About
Contact & Profiles
A5089711560
Research Areas
- Tuberous Sclerosis Complex Research
- Vaccine Coverage and Hesitancy
- Renal and related cancers
- Viral Infections and Outbreaks Research
- Renal cell carcinoma treatment
- Diabetes and associated disorders
- Pancreatic function and diabetes
- Diabetes Treatment and Management
Centro Hospitalar de Entre o Douro e Vouga E.P.E.
2020-2021
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are the most recently approved drug class for treatment of type diabetes mellitus (T2D). Although they largely well-tolerated, their intake has been associated with euglycemic diabetic ketoacidosis (DKA) in some rare cases. We report case a 70-year-old male and no history DKA, who started therapy empagliflozin one day before presenting acute pancreatitis laboratory findings consistent DKA. SGLT2i can induce DKA from first dose. Given...
10.3390/clinpract11020031
article
EN
cc-by
Clinics and Practice
2021-04-06
10.24950/rspmi/imagem/201/19/1/2020
article
PT
Medicina Interna
2020-03-11
10.24950/ce/208/21/3/2021
article
PT
Medicina Interna
2021-09-21
Coming Soon ...